Richard Penson, MD of Massachusetts General Hospital @MassGeneralNews discusses a randomized phase III of olaparib versus nonplatinum chemotherapy in patients with platinum-sensitive relapsed ovarian cancer and a germline BRCA1/2 mutation (SOLO3).
Read here:Â https://ascopubs.org/doi/full/10.1200/JCO.19.02745